Page last updated: 2024-10-25

chlorthalidone and Cardio-Renal Syndrome

chlorthalidone has been researched along with Cardio-Renal Syndrome in 2 studies

Chlorthalidone: A benzenesulfonamide-phthalimidine that tautomerizes to a BENZOPHENONES form. It is considered a thiazide-like diuretic.

Cardio-Renal Syndrome: Condition where a primary dysfunction of either heart or kidney results in failure of the other organ (e.g., HEART FAILURE with worsening RENAL INSUFFICIENCY).

Research Excerpts

Excerpt	Relevance	Reference
"The main treatment strategy in type 1 cardiorenal syndrome (CRS1) is vascular decongestion."	3.11	The Effect in Renal Function and Vascular Decongestion in Type 1 Cardiorenal Syndrome Treated with Two Strategies of Diuretics, a Pilot Randomized Trial. ( Chávez-Alonso, G; Chávez-Iñiguez, JS; De la Torre-Quiroga, A; de Quevedo, AA; Font-Yañez, JJ; García-García, G; Gómez-Fregoso, J; Ibarra-Estrada, M; Maggiani-Aguilera, P; Romero-González, G; Romero-Muñóz, A; Sánchez-Villaseca, S, 2022)

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	1 (50.00)	2.80

Authors

Authors	Studies
Chávez-Iñiguez, JS	1
Ibarra-Estrada, M	1
Sánchez-Villaseca, S	1
Romero-González, G	1
Font-Yañez, JJ	1
De la Torre-Quiroga, A	1
de Quevedo, AA	1
Romero-Muñóz, A	1
Maggiani-Aguilera, P	1
Chávez-Alonso, G	1
Gómez-Fregoso, J	1
García-García, G	1
García-Blas, S	1
Bonanad, C	1
Llàcer, P	1
Ventura, S	1
Núñez, JM	1
Sánchez, R	1
Chamorro, C	1
Fácila, L	1
de la Espriella, R	1
Vaquer, JM	1
Cordero, A	1
Roqué, M	1
Ortiz, V	1
Racugno, P	1
Bodí, V	1
Valero, E	1
Santas, E	1
Moreno, MDC	1
Miñana, G	1
Carratalá, A	1
Bondanza, L	1
Payá, A	1
Cardells, I	1
Heredia, R	1
Pellicer, M	1
Valls, G	1
Palau, P	1
Bosch, MJ	1
Raso, R	1
Sánchez, A	1
Bertomeu-González, V	1
Bertomeu-Martínez, V	1
Montagud-Balaguer, V	1
Albiach-Montañana, C	1
Pendás-Meneau, J	1
Marcaida, G	1
Cervantes-García, S	1
San Antonio, R	1
de Mingo, E	1
Chorro, FJ	1
Sanchis, J	1
Núñez, J	1

Clinical Trials (2)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Effect on Kidney Function Recovery Guiding Decongestion With VExUS in Patients With Cardiorenal Syndrome 1[NCT05927285]		140 participants (Actual)	Interventional	2022-03-20	Completed
The Effect in Renal Function on Patients With Type 1 Cardiorenal Syndrome Treated With Two Strategies of Furosemide. A Randomized Controled Trial[NCT04393493]	Phase 2	80 participants (Actual)	Interventional	2017-07-01	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

An Elevation of at Least 0.3 mg/dl of Serum Creatinine From Day One of Intervention Compared With Serum Creatinine at 96hrs After Intervention Started

(NCT04393493)
Timeframe: 96 hours after intervention started

Intervention	Participants (Count of Participants)
Stepped Furosemide	20
Diuretics Combined	24

Change in 24 Hour Urine Output at 96 Hours After Intervention Started From 24 Hour Urine Output One Day Before Intervention Initiation)

Urine output was collected through an urinary catheter and measured and registered by a nurse. The sum of these registrations from 7 am from one day to 7 am of the next day was considered the 24 hour urinary output (NCT04393493)
Timeframe: 96 hours after intervention started

Intervention	ml (Mean)
Stepped Furosemide	125
Diuretics Combined	200

Change in Serum Bicarbonate Levels Measured at Day One of Intervention From Serum Bicarbonate Levels Measured at 96 Hrs After Intervention Started.

Calculated as serum bicarbonate levels at day one of intervention minus bicarbonate levels at 96 hrs after intervention started. (NCT04393493)
Timeframe: 96 hours after intervention started

Intervention	mEq/L (Mean)
Stepped Furosemide	2.9
Diuretics Combined	3

Change in Serum Brain Natriuretic Peptide Levels at Baseline From Serum Brain Natriuretic Peptide Levels at 96 Hours After Intervention Started

Baseline levels were defined as the measurement at hospital admission. Calculated as serum brain natriuretic peptide levels at baseline minus serum brain natriuretic peptide levels at 96 hours after intervention started (NCT04393493)
Timeframe: 96 hours after intervention started

Intervention	ng/dl (Mean)
Stepped Furosemide	-1344
Diuretics Combined	-1378

Change in Serum Calcium Levels Measured at Day One of Intervention From Serum Calcium Levels Measured at 96 Hrs After Intervention Started.

Calculated as serum calcium levels at day one of intervention minus serum calcium levels at 96 hrs after intervention started. (NCT04393493)
Timeframe: 96 hours after intervention started

Intervention	mg/dl (Mean)
Stepped Furosemide	0.15
Diuretics Combined	-0.05

Change in Serum Chloride Levels Measured at Day One of Intervention From Serum Chloride Levels Measured at 96 Hrs After Intervention Started.

Calculated as serum chloride levels at day one of intervention minus serum chloride levels at 96 hrs after intervention started. (NCT04393493)
Timeframe: 96 hours after intervention started

Intervention	mEq/L (Mean)
Stepped Furosemide	-0.6
Diuretics Combined	-0.4

Change in Serum Copeptin Levels at Day One of Intervention From Serum Copeptin Levels Measured at 96 Hrs After Intervention Started.

Calculated as serum copeptin levels at day one minus serum copeptin levels measured at 96 hrs after intervention started (NCT04393493)
Timeframe: 96 hours after intervention started

Intervention	ng/dl (Mean)
Stepped Furosemide	1.1
Diuretics Combined	-16

Change in Serum Creatinine at Day One of Intervention From Serum Creatinine at 96 Hrs After Intervention Started

Calculated as serum creatinine at day one minus serum creatinine at 96 hrs after intervention started (NCT04393493)
Timeframe: 96 hours after intervention started

Intervention	mg/dl (Mean)
Stepped Furosemide	0.02
Diuretics Combined	0.2

Change in Serum Lactate Levels Measured at Day One of Intervention From Serum Lactate Levels Measured at 96 Hrs After Intervention Started.

Calculated as serum lactate levels at day one of intervention minus serum lactate levels at 96 hrs after intervention started. (NCT04393493)
Timeframe: 96 hours after intervention started

Intervention	mmol/L (Mean)
Stepped Furosemide	0
Diuretics Combined	0.1

Change in Serum Magnesium Levels Measured at Day One of Intervention From Serum Magnesium Levels Measured at 96 Hrs After Intervention Started.

Calculated as serum magnesium levels at day one of intervention minus serum magnesium levels at 96 hrs after intervention started. (NCT04393493)
Timeframe: 96 hours after intervention started

Intervention	mg/dl (Mean)
Stepped Furosemide	0.07
Diuretics Combined	-0.04

Change in Serum Partial Pressure of Carbon Dioxide Measured at Day One of Intervention From Serum Partial Pressure of Carbon Dioxide Measured at 96 Hrs After Intervention Started.

Calculated as serum partial pressure of carbon dioxide at day one of intervention minus serum partial pressure of carbon dioxide at 96 hrs after intervention started. (NCT04393493)
Timeframe: 96 hours after intervention started

Intervention	mmHg (Mean)
Stepped Furosemide	1
Diuretics Combined	3

Change in Serum pH Value Measured at Day One of Intervention From Serum pH Value Measured at 96 Hrs After Intervention Started.

Calculated as serum pH value at day one of intervention minus serum pH value at 96 hrs after intervention started. (NCT04393493)
Timeframe: 96 hours after intervention started

Intervention	units (Mean)
Stepped Furosemide	0.03
Diuretics Combined	0.02

Change in Serum Potassium Levels Measured at Day One of Intervention From Serum Potassium Levels Measured at 96 Hrs After Intervention Started.

Calculated as serum potassium levels at day one of intervention minus serum potassium levels at 96 hrs after intervention started. (NCT04393493)
Timeframe: 96 hours after intervention started

Intervention	mEq/L (Mean)
Stepped Furosemide	-0.2
Diuretics Combined	-0.4

Change in Serum Sodium Levels Measured at Day One of Intervention From Serum Sodium Levels Measured at 96 Hrs After Intervention Started.

Calculated as serum sodium levels at day one of intervention minus serum sodium levels at 96 hrs after intervention started. (NCT04393493)
Timeframe: 96 hours after intervention started

Intervention	mEq/L (Mean)
Stepped Furosemide	-1.2
Diuretics Combined	0.2

Change in Serum Urea Levels Measured at Day One of Intervention From Serum Urea Levels Measured at 96 Hrs After Intervention Started.

Calculated as serum urea levels at day one of intervention minus serum urea levels at 96 hrs after intervention started. (NCT04393493)
Timeframe: 96 hours after intervention started

Intervention	mg/dl (Mean)
Stepped Furosemide	13
Diuretics Combined	18

In Hospital Mortality Defined as Number of Dead Patients From Day One of Intervention and Before Discharge

(NCT04393493)
Timeframe: From day one of intervention up to discharge, an average of 1 week

Intervention	Participants (Count of Participants)
Stepped Furosemide	4
Diuretics Combined	4

Mortality During Follow up Defined as Number of Dead Patients After Discharge

(NCT04393493)
Timeframe: From day one after discharge up to an average of 161 days

Intervention	Participants (Count of Participants)
Stepped Furosemide	9
Diuretics Combined	12

Number of Days From the Beginning of the Intervention Until Patients Referred Dyspnea Improvement or a Reduction in Supplementary Oxygen Requirements Was Made.

"Dyspnea improvement was referred by the patient as the clinician asked them do you feel more or less difficult to breathe? or if the liters per minute or the fraction of inspired supplementary oxygen necessary maintain an oxygen saturation >90% were diminished" (NCT04393493)
Timeframe: Up to 4 days after intervention started

Intervention	days (Mean)
Stepped Furosemide	4
Diuretics Combined	4

Number of Participants With Renal Function Recovery Defined as a Return to Individual Baseline Serum Creatinine Values

Comparing patient's baseline serum creatinine (previous serum creatinine of 3 months ago and up to a year ago) with creatinine measurements every 24 hours during intervention (4 days) (NCT04393493)
Timeframe: Up to 96 hours after intervention started

Intervention	Participants (Count of Participants)
Stepped Furosemide	8
Diuretics Combined	5

Number of Patients That Achieved >30% Reduction in Brain Natriuretic Compared With Baseline Levels

Baseline levels were defined as the measurement at hospital admission (NCT04393493)
Timeframe: Up to 96 hours after intervention started

Intervention	Participants (Count of Participants)
Stepped Furosemide	5
Diuretics Combined	7

Number of Patients That Required Renal Replacement Therapy of Any Type During Intervention (4 Days).

The requirement of renal replacement therapy was assessed by the nephrology team in charge (NCT04393493)
Timeframe: Up to 96 hours after intervention started

Intervention	Participants (Count of Participants)
Stepped Furosemide	7
Diuretics Combined	6

Number of Patients Whose Interventions Were Stopped Because Clinical Improvement Was Achieved Before 96 Hours as Assessed by de Clinical Judgement of the Medical Team in Charge.

Clinical improvement was referred as remission of symptoms with achievement of 24 hour urine output equal or greater than 3000 milliliters (NCT04393493)
Timeframe: From the beginning of intervention and before 96 hours after that

Intervention	Participants (Count of Participants)
Stepped Furosemide	5
Diuretics Combined	7

Number of Patients With Dyspnea Improvement as Referred by the Patient or Reduction in Supplementary Oxygen Requirements at 96 Hours After Intervention Started

"Dyspnea improvement was referred by the patient as the clinician asked them do you feel more or less difficult to breathe? or if the liters per minute or the fraction of inspired supplementary oxygen necessary to maintain an oxygen saturation >90% were diminished" (NCT04393493)
Timeframe: Up to 96 hours after intervention started

Intervention	Participants (Count of Participants)
Stepped Furosemide	27
Diuretics Combined	27

Number of Patients With Dyspnea Improvement as Referred by the Patient or Reduction in Supplementary Oxygen Requirements Before Day 3 of Intervention

Intervention	Participants (Count of Participants)
Stepped Furosemide	2
Diuretics Combined	7

Trials

2 trials available for chlorthalidone and Cardio-Renal Syndrome

Article	Year
The Effect in Renal Function and Vascular Decongestion in Type 1 Cardiorenal Syndrome Treated with Two Strategies of Diuretics, a Pilot Randomized Trial. BMC nephrology, 2022, 01-03, Volume: 23, Issue:1 Topics: Adult; Cardio-Renal Syndrome; Chlorthalidone; Diuretics; Double-Blind Method; Drug Administration Sc	2022
The Effect in Renal Function and Vascular Decongestion in Type 1 Cardiorenal Syndrome Treated with Two Strategies of Diuretics, a Pilot Randomized Trial. BMC nephrology, 2022, 01-03, Volume: 23, Issue:1 Topics: Adult; Cardio-Renal Syndrome; Chlorthalidone; Diuretics; Double-Blind Method; Drug Administration Sc	2022
The Effect in Renal Function and Vascular Decongestion in Type 1 Cardiorenal Syndrome Treated with Two Strategies of Diuretics, a Pilot Randomized Trial. BMC nephrology, 2022, 01-03, Volume: 23, Issue:1 Topics: Adult; Cardio-Renal Syndrome; Chlorthalidone; Diuretics; Double-Blind Method; Drug Administration Sc	2022
The Effect in Renal Function and Vascular Decongestion in Type 1 Cardiorenal Syndrome Treated with Two Strategies of Diuretics, a Pilot Randomized Trial. BMC nephrology, 2022, 01-03, Volume: 23, Issue:1 Topics: Adult; Cardio-Renal Syndrome; Chlorthalidone; Diuretics; Double-Blind Method; Drug Administration Sc	2022
Diuretic Strategies in Acute Heart Failure and Renal Dysfunction: Conventional vs Carbohydrate Antigen 125-guided Strategy. Clinical Trial Design. Revista espanola de cardiologia (English ed.), 2017, Volume: 70, Issue:12 Topics: Acetazolamide; Acute Disease; CA-125 Antigen; Cardio-Renal Syndrome; Chlorthalidone; Creatinine; Diu	2017